

Impact of discharge medication counseling in the cardiology unit of a tertiary hospital in Brazil: A randomized controlled trial

Aline F. Bonetti,¹ Bruna Q. Bagatim,¹ Antonio M. Mendes,¹ Inajara Rotta,¹ Renata C. Reis,¹ Maria Luiza D. Fávero,¹ Fernando Fernandez-Llímós,² Roberto Pontarolo^{1,*}

¹Departamento de Farmácia, Universidade Federal do Paraná, Curitiba, PR, Brasil. ²Departamento de Socio-Farmácia, Instituto de Pesquisa de Medicamentos (iMed. Ulisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal.

Bonetti AF, Bagatim BQ, Mendes AM, Rotta I, Reis RC, Fávero ML, et al. Impact of discharge medication counseling in the cardiology unit of a tertiary hospital in Brazil: A randomized controlled trial. *Clinics*. 2018;73:e325

*Corresponding author. E-mail: pontarolo@ufpr.br

OBJECTIVES: This study aimed to evaluate the impact of pharmacist-provided discharge counseling on mortality rate, hospital readmissions, emergency department visits, and medication adherence at 30 days post discharge.

METHODS: This randomized controlled trial was approved by the local ethics committee and included patients aged 18 years or older admitted to the cardiology ward of a Brazilian tertiary hospital. The intervention group received a pharmacist-led medication counseling session at discharge and a telephone follow-up three and 15 days after discharge. The outcomes included the number of deaths, hospital readmissions, emergency department visits, and medication adherence. All outcomes were evaluated during a pharmacist-led ambulatory consultation performed 30 days after discharge.

RESULTS: Of 133 patients, 104 were included in the analysis (51 and 53 in the intervention and control groups, respectively). The intervention group had a lower overall readmission rate, number of emergency department visits, and mortality rate, but the differences were not statistically significant ($p > 0.05$). However, the intervention group had a significantly lower readmission rate related to heart disease (0% vs. 11.3%, $p = 0.027$), despite the small sample size. Furthermore, medication counseling contributed significantly to improved medication adherence according to three different tools ($p < 0.05$).

CONCLUSIONS: Pharmacist-provided discharge medication counseling resulted in better medication adherence scores and a lower incidence of cardiovascular-associated hospital readmissions, thus representing a useful service for cardiology patients.

KEYWORDS: Patient Discharge; Medication Adherence; Patient Readmission; Counseling; Pharmacists.

INTRODUCTION

Medication errors are an important risk factor for hospitalization and mortality (1,2). Several factors contribute to increased readmission rates, including time to primary care follow-up, adverse drug events (3,4), medication nonadherence (5), medication discrepancies (6,7), insufficient discharge planning (8), and lack of continuity in care (9). Medical conditions associated with high rates of re-hospitalization include congestive heart failure, acute myocardial infarction (AMI), pneumonia, diabetes, and chronic obstructive pulmonary disease (9).

Up to 67% of patients admitted to hospitals have medication discrepancies that often persist at discharge (10).

One observational study reported that patients with medication discrepancies had a 30-day hospital readmission rate of 14.3%, compared with 6.1% in patients without discrepancies (6). The consequences of these issues affect patient safety as well as the quality and cost of care (6,11). The World Health Organization estimates that only 50% of individuals with chronic diseases adhere to their medication regimen (12). Recent studies have demonstrated that adherence to cardioprotective medications, such as statins and clopidogrel, is poor in the first year after acute coronary syndrome. After AMI, nearly 24% of patients do not fill their medications within seven days of discharge, and one-third of patients decide to stop at least one medication in the first month (5,13).

Pharmacists may play a significant role in the transition of care, especially in reducing readmissions by ensuring that appropriate, evidence-based pharmacotherapy regimens have been prescribed during hospitalization, identifying medication errors, and performing medication reconciliation (8).

The results of several studies suggest that medication counseling before hospital discharge reduces the incidence of patient medication discrepancies and adverse drug events (4,7). Counseling also improves adherence (14,15), decreases readmission rates (1,16) and mortality (5), and consequently

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

No potential conflict of interest was reported.

Received for publication on August 17, 2017. Accepted for publication on November 8, 2017

DOI: 10.6061/clinics/2018/e325



results in cost savings (17,18); however, other reports have suggested that counseling has little or no effect (19,20).

Medication counseling can ensure that patients are appropriately educated about their medications. However, most previous studies have been conducted in high-income countries, and the endpoints were evaluated via telephone interviews. Therefore, the aim of this trial was to assess the impact of pharmacist-led medication counseling at hospital discharge on mortality rate, hospital readmissions (related and unrelated to heart disease), emergency department visits (related and unrelated to heart disease), and medication adherence in a developing country.

METHODS

This randomized controlled trial was performed according to CONSORT guidelines and was conducted in a tertiary hospital in Curitiba, Brazil, from February to December 2015. This hospital has 360 beds and admits approximately 30 patients per month on the cardiology ward. Patients aged 18 years and older were eligible if they were admitted to a specialized cardiology ward due to stable angina, acute coronary syndrome, congestive heart failure, valvular disease, arrhythmias, or hypertension. The exclusion criteria included patients with cognitive impairment and without a caregiver, palliative care status, and subjects who refused to participate in this study. Patients transferred to other clinical specialties or institutions and those who were not discharged from the hospital before the end of the study were also excluded.

The sample size was calculated considering 5.0% type I and 20% type II error (80% power) rates based on hospital readmission rates reported in the literature, resulting in 53 patients in each group. Following the randomization procedures, the participants were randomly assigned to one of two groups. Eligible patients who provided informed consent were allocated to either the intervention group or control group in a 1:1 ratio using a random number list generated by a third person using *Microsoft Office Excel 2010*[®]. The sequence of inclusion corresponded to the hospital admission order. Two cardiovascular pharmacy residents were responsible for patient enrollment according to the eligibility criteria and for performing the intervention. These pharmacy residents were in the department daily, and they received coaching during the first year of residency.

Patients who were allocated to the intervention group or their caregivers received individual counseling sessions regarding the discharge prescriptions. These sessions included a thorough assessment of the pharmacotherapy and interventions from cardiologists in order to correct any medication issues, as well as an explanation about the indications, benefits, therapeutic targets, dose, dosing schedule, routes, storage, length of therapy, refill pharmacy, and possible adverse drug events for each prescribed drug. A leaflet containing the information provided in the verbal counseling was delivered by the pharmacists. Subsequently, patients were contacted by telephone three and 15 days post-discharge to reinforce the previous counseling session. All pharmacist interventions were performed and described according to the Descriptive Elements of Pharmacist Interventions Characterization Tool (DEPICT) (21).

The control group received usual care from pharmacists and other healthcare providers. During the hospitalization, all patients, including those from the control group, received pharmaceutical interventions as necessary. At the time of hospital discharge, patients from both groups were scheduled

for an appointment 30 days post-discharge in the Pharmaceutical Care Ambulatory Clinic of the same hospital. During this appointment, the pharmacist team for the ambulatory clinic collected data regarding the participant outcomes and performed counseling for both groups as necessary. Subsequently, all patients were followed equally by the ambulatory clinic. There were five trained pharmacists in this setting, including one of the residents who provided the intervention.


The primary endpoints were mortality rate, hospital readmissions (related and unrelated to heart disease), and emergency department visits (related and unrelated to heart disease) within 30 days. We asked the patients whether they visited emergency departments during this period and whether they were admitted to another hospital.

The secondary endpoint was medication adherence based on the results of the *MedTake* (22), Beliefs about Medicines Questionnaire (BMQ) (23), and Adherence to Refills and Medications Scale (ARMS) (24) instruments, all completed 30 days post-discharge. The *MedTake* test is a quantitative assessment of drug-taking procedures for oral prescriptions that is used to screen for medication adherence problems. The test evaluates dosage (number of dosage units), indications, food or water co-ingestion, and regimens. Each test is scored as the percentage of correct actions (0%: zero adherence; 100%: total adherence) (22). To better interpret the overall results, we divided the results into *MedTake* 1, and *MedTake* 2, defined as the percentage of drugs that the patient was taking properly and the percentage of drugs for which the patient was aware of the indications, respectively. The BMQ is a questionnaire composed of two subscales: a five-item necessity scale to assess beliefs about the necessity for medication and a six-item concerns scale to assess beliefs about the danger of dependence and the disruptive effects of medication. Each item is scored on a five-point scale (1=strongly disagree, 2=disagree, 3=uncertain, 4=agree and 5=strongly agree); the final result is obtained by the quotient between the percentage of the sum of "necessity" and "concern" questions (23). Higher scores indicate greater awareness of the necessity for taking the medications, decreased concern regarding the possible negative effects, and better medication adherence. Finally, the ARMS instrument is a medication adherence scale intended for patients with chronic medical conditions. It includes a total of 14 items, each of which is structured with responses "none," "some," "most," or "all" of the time, which are assigned values from 1 to 4, respectively. The questionnaire contains questions about the frequency of medication withdrawal in healthcare institutions ("refill") and about forgetfulness in taking medications ("taking") (24). Patients with better medication adherence have scores near 12, whereas patients with no adherence have scores of 48.

Statistical analyses were conducted using SPSS Statistics for Windows, version 22.0. Kolmogorov-Smirnov tests were used to assess the normality of the distribution of the investigated parameters. Student's *t* and Mann-Whitney tests were used for continuous data as appropriate, and categorical variables were assessed using chi-square and Fisher's exact tests. *P* values lower than 0.05 were considered statistically significant.

Ethics approval

This trial was performed in accordance with the standards of the institution's ethics committee (approval number: 40431015.8.0000.0096), the national research committee, and the 1983 Helsinki declaration and its later amendments or comparable ethical standards.



*For the secondary endpoint analysis, we excluded two participants from the intervention group: one was an inpatient, and the adherence tools were not completed for the second patient. Four patients in the control group were excluded in the secondary analysis because three died, and the adherence tools were not completed for the remaining patient.

Figure 1 - Flow diagram of the intervention and control groups in the randomized trial.

RESULTS

Of the 167 eligible patients recruited between February and November 2015, 133 agreed to participate, and 34 were excluded. A total of 66 and 67 patients were allocated to the intervention and control groups, respectively, and patient follow-up occurred through December 2015 (Figure 1).

There were no statistically significant differences in baseline characteristics between the two groups (Table 1). The mean age of the participants was 65 years, most were men, and all of the participants were on polypharmacy. The most frequent reason for hospitalization was AMI, followed by unstable angina, congestive heart failure, and atrial fibrillation.



Table 1 - Patient characteristics at baseline.

Variable*	Intervention (n=51)	Control (n=53)	p***
Age (years)	65 (± 10)	65 (± 13)	0.939
Men, n (%)	35 (68.6)	34 (64.2)	0.629
Number of comorbidities	4 (± 1)	4 (± 2)	0.929
Number of medications at discharge	7 (± 2)	8 (± 3)	0.430
Number of medications at ambulatory follow-up**	8 (± 3)	9 (± 3)	0.250
Days of hospitalization	10 (± 9)	12 (± 9)	0.273
Presence of caregiver, n (%)	14 (28)	17 (34)	0.517

* Mean and SD are reported for continuous data.

** n=49 in each group.

*** Statistically significant if $p < 0.05$.

Table 2 - Primary endpoint results.

Endpoints*	Intervention (n=51)	Control (n=53)	p**
Emergency department visits related to heart disease	0	4 (7.5)	0.118
Emergency department visits not related to heart disease	3 (5.9)	1 (1.9)	0.289
Total hospital readmissions	4 (7.8)	7 (13.2)	0.374
Hospital readmissions related to heart disease	0 (0)	6 (11.3)	0.027
Hospital readmissions not related to heart disease	4 (7.8)	1 (1.9)	0.156
Deaths	0 (0)	3 (5.7)	0.243

* Data are reported as absolute and relative numbers (%).

** Statistically significant if $p < 0.05$.

Table 3 - Secondary endpoint results.

Endpoints*	Intervention (n=49)	Control (n=49)	p**
Total MedTake	92.1 (± 9.9)	58.5 (± 31.9)	<0.001
MedTake 1	95.2 (± 8.6)	64.7 (± 37.1)	<0.001
MedTake 2	85.2 (± 21.5)	44.5 (± 34.8)	<0.001
BMQ	1.8 (± 0.6)	1.6 (± 0.5)	0.028
ARMS	13 (± 2)	15 (± 4)	0.001

* Mean and SD are reported for the data.

** Statistically significant if $p < 0.05$.

Abbreviations: ARMS: Adherence to Refills and Medications Scale;

BMQ: Beliefs about Medicines Questionnaire.

The most common comorbidities were hypertension, diabetes, and dyslipidemia.

There were three deaths during the 30 days post-discharge, all in the control group. These patients were included in the primary endpoint analysis, but the difference between the intervention and control groups was not statistically significant ($p=0.243$; Table 2).

The rate of hospital readmissions related to heart disease was significantly lower in the intervention group than in the control group ($p=0.027$). Overall readmissions and emergency department visits related to heart disease were higher in the control group, but the differences were not statistically significant ($p=0.374$ and $p=0.118$, respectively; Table 2).

The mean scores of each adherence instrument revealed that the intervention group was significantly more adherent to medications than the control group ($p < 0.05$; Table 3).

DISCUSSION

This study revealed that medication counseling at discharge decreased early readmission rates, especially related to heart disease, and improved medication adherence. These outcomes were evaluated during a pharmaceutical appointment, unlike previous studies, indicating the potential for pharmacotherapeutic follow-up of patients. This is the first

study to evaluate the impact of medication counseling on readmission rates, emergency department visits, deaths, and medication adherence using three different tools.

According to similar studies, pharmacist-led medication review, patient counseling, and telephone follow-up are associated with lower readmission rates after hospital discharge; however, some of these results were not statistically significant (19,25-27), and some of these studies were conducted as non-randomized trials (1,15,27).

A prospective study reported that older age, history of diabetes, a greater number of prescriptions before AMI, and history of congestive heart failure are associated with increased one-year mortality. Patients who received discharge counseling from pharmacists had a lower risk of one-year mortality ($p=0.001$) (5). Our study did not observe a statistically significant reduction in mortality among patients with these characteristics; however, we evaluated early mortality in a randomized controlled trial design, whereas the previous study was a cohort design that analyzed one-year mortality following AMI.

A similar randomized trial revealed that patients who received discharge medication counseling from nurses and telephone follow-up from pharmacists exhibited lower rates of hospital utilization than usual care participants ($p=0.009$), but there was no difference in early readmission rates ($p=0.090$) (17). Another study evaluated the impact of the pharmacy team in transition-of-care settings and demonstrated reduced composite emergency department visits and inpatient readmissions ($p=0.022$) but reported no significant differences in hospital readmission rates separately ($p=0.43$) (28). Conversely, our study revealed lower 30-day readmission rates due to cardiac diseases in patients who were allocated to the intervention group, emphasizing that medication counseling may be important for cardiology patients with polypharmacy to reduce readmission rates caused by improper use of medication.

We also observed that discharge counseling and pharmacotherapy follow-up by phone were essential for medication



adherence. The intervention group had significantly higher mean total *MedTake*, *MedTake* 1, and *MedTake* 2 percentages compared with the control group, indicating that the pharmacist-led counseling contributed to an increased patient understanding of the medication-taking process and the indications for each medication. Other factors may contribute to medication adherence, including patient resources, attitudes, beliefs, perceptions, and expectations towards medication (29). However, we observed that the intervention group was significantly more adherent to their medications than the control group based on the BMQ and ARMS results.

The limitations of this study include a small patient population that, despite exceeding the minimum sample size calculations, may have resulted in an underestimation of the effect of the intervention. However, our trial is underpowered to adequately study mortality, other causes of hospital readmissions, and emergency department visits. We note that not everyone in the ambulatory setting was blinded to the study allocation, but the primary outcomes are objective and consequently were not affected by the lack of blinding. Another limitation is that the intervention group could have been affected by the Hawthorn effect, contributing to the positive results.

The results of this study revealed that discharge medication counseling performed by pharmacists decreased 30-day hospital readmissions, particularly those related to cardiac disease, and improved medication adherence in cardiology patients under polypharmacy. Transition of care is a high-risk situation for many patients, and abundant discharge counseling is needed. The involvement of pharmacists in the transition of care is advisable to reduce re-hospitalization related to inappropriate use of medications.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the Program of Multidisciplinary Residency of the Hospital de Clínicas (Universidade Federal do Paraná) and the Hospital Pharmacy Unit for allowing us to perform this study. We also extend our sincere thanks to the patients who participated in our study.

AUTHOR CONTRIBUTIONS

Bonetti AF and Pontarolo R had full access to all of the study data and take responsibility for the integrity of the data and the accuracy of the data analysis. Bonetti AF, Bagatim BQ, Mendes AE, Reis RC, and Favero ML were responsible for the study concept and design. Bonetti AF, Bagatim BQ and Mendes AE were responsible for the acquisition of the data. Bonetti AF, Mendes AE and Rotta I were responsible for the analysis and interpretation of the data. Bonetti AF, Bagatim BQ and Mendes AE were responsible for the manuscript drafting. Bonetti AF, Bagatim BQ, Mendes AE, Rotta I, Reis RC, Favero ML, Fernandez-Llimos F and Pontarolo R were responsible for the critical revision of the manuscript for important intellectual content. Fernandez-Llimos and Pontarolo were responsible for the study supervision.

REFERENCES

- Kirkham HS, Clark BL, Paynter J, Lewis GH, Duncan I. The effect of a collaborative pharmacist-hospital care transition program on the likelihood of 30-day readmission. *Am J Health Syst Pharm*. 2014;71(9):739-45, <http://dx.doi.org/10.2146/ajhp130457>.
- Makary MA, Daniel M. Medical error — the third leading cause of death in the US. *BMJ*. 2016;353:i2139, <http://dx.doi.org/10.1136/bmj.i2139>.
- Kripalani S, Rounie CL, Dalal AK, Cawthon C, Businger A, Eden SK, et al. Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trial. *Ann Intern Med*. 2012;157(1):1-10, <http://dx.doi.org/10.7326/0003-4819-157-1-201207030-00003>.
- Armor BL, Wight AJ, Carter SM. Evaluation of adverse drug events and medication discrepancies in transitions of care between hospital discharge and primary care follow-up. *J Pharm Pract*. 2016;29(2):132-7, <http://dx.doi.org/10.1177/0897190014549836>.
- Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. *Circulation*. 2008;117(8):1028-36, <http://dx.doi.org/10.1161/CIRCULATIONAHA.107.706820>.
- Coleman EA, Smith JD, Raha D, Min SJ. Posthospital medication discrepancies: prevalence and contributing factors. *Arch Intern Med*. 2005;165(16):1842-7, <http://dx.doi.org/10.1001/archinte.165.16.1842>.
- Eggink RN, Lenderink AW, Widdershoven JW, van den Beemt PM. The effect of a clinical pharmacist discharge service on medication discrepancies in patients with heart failure. *Pharm World Sci*. 2010;32(6):759-66, <http://dx.doi.org/10.1007/s11096-010-9433-6>.
- Wiggins BS, Rodgers JE, DiDomenico RJ, Cook AM, Page RL. Discharge counseling for patients with heart failure or myocardial infarction: a best practices model developed by members of the American College of Clinical Pharmacy's Cardiology Practice and Research Network based on the Hospital to Home (H2H) Initiative. *Pharmacotherapy*. 2013;33(5):558-80, <http://dx.doi.org/10.1002/phar.1231>.
- Snyderman D, Salzman B, Mills G, Hersh L, Parks S. Strategies to help reduce hospital readmissions. *J Fam Pract*. 2014;63(8):430-8a.
- Tam VC, Knowles SR, Cornish PL, Fine N, Marchesano R, Etchells EE. Frequency, type and clinical importance of medication history errors at admission to hospital: a systematic review. *CMAJ*. 2005;173(5):510-5, <http://dx.doi.org/10.1503/cmaj.045311>.
- Hesselink G, Zegers M, Vernooij-Dassen M, Barach P, Kalkman C, Flink M, et al. Improving patient discharge and reducing hospital readmissions by using Intervention Mapping. *BMC Health Serv Res*. 2014;14:389, <http://dx.doi.org/10.1186/1472-6963-14-389>.
- De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action. *Eur J Cardiovasc Nurs*. 2003;2(4):323, [http://dx.doi.org/10.1016/S1474-5151\(03\)00091-4](http://dx.doi.org/10.1016/S1474-5151(03)00091-4).
- Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. *Arch Intern Med*. 2006;166(17):1842-7, <http://dx.doi.org/10.1001/archinte.166.17.1842>.
- Shah M, Norwood CA, Farias S, Ibrahim S, Chong PH, Fogelfeld L. Diabetes transitional care from inpatient to outpatient setting: pharmacist discharge counseling. *J Pharm Pract*. 2013;26(2):120-4, <http://dx.doi.org/10.1177/0897190012451907>.
- Warden BA, Freels JP, Furuno JP, Mackay J. Pharmacy-managed program for providing education and discharge instructions for patients with heart failure. *Am J Health Syst Pharm*. 2014;71(2):134-9, <http://dx.doi.org/10.2146/ajhp130103>.
- Sánchez Ulayar A, Gallardo López S, Pons Llobet N, Murgadella Sancho A, Campins Bernadàs L, Merino Méndez R. Pharmaceutical intervention upon hospital discharge to strengthen understanding and adherence to pharmacological treatment. *Farm Hosp*. 2012;36(3):118-123, <http://dx.doi.org/10.1016/j.farma.2011.02.003>.
- Jack BW, Chetty VK, Anthony D, Greenwald, JL, Sanchez GM, Johnson AE, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. *Ann Intern Med*. 2009;150(3):178-87, <http://dx.doi.org/10.7326/0003-4819-150-3-200902030-00007>.
- Szkladz A, Carey K, Ackerbauer K, Heelon M, Friderici J, Kopcza K. Impact of pharmacy student and resident-led discharge counseling on heart failure patients. *J Pharm Pract*. 2013;26(6):574-9, <http://dx.doi.org/10.1177/0897190013491768>.
- Farris KB, Carter BL, Xu Y, Dawson JD, Shelsky C, Weetman DB, et al. Effect of a care transition intervention by pharmacists: an RCT. *BMC Health Serv Res*. 2014;14:406, <http://dx.doi.org/10.1186/1472-6963-14-406>.
- Wong MC, Liu KQ, Wang HH, Lee CL, Kwan MW, Lee KW, et al. Effectiveness of a pharmacist-led drug counseling on enhancing anti-hypertensive adherence and blood pressure control: a randomized controlled trial. *J Clin Pharmacol*. 2013;53(7):753-61, <http://dx.doi.org/10.1002/jcph.101>.
- Rotta I, Salgado TM, Felix DC, Souza TT, Correr CJ, Fernandez-Llimos F. Ensuring consistent reporting of clinical pharmacy services to enhance reproducibility in practice: an improved version of DEPICT. *J Eval Clin Pract*. 2015;21(4):584-90, <http://dx.doi.org/10.1111/jep.12339>.
- Raehl CL, Bond CA, Woods T, Patry RA, Sleeper RB. Individualized drug use assessment in the elderly. *Pharmacotherapy*. 2002;22(10):1239-48, <http://dx.doi.org/10.1592/phco.22.15.1239.33473>.
- Salgado T, Marques A, Galdes L, Benrimoj S, Horne R, Fernandez-Llimos F. Cross-cultural adaptation of The Beliefs about Medicines Questionnaire into Portuguese. *Sao Paulo Med J*. 2013;131(2):88-94, <http://dx.doi.org/10.1590/S1516-31802013000100018>.
- Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. *Value Health*. 2009;12(1):118-23, <http://dx.doi.org/10.1111/j.1524-4733.2008.00400.x>.
- Schnipper JL, Kirwin JL, Cotugno MC, Wahlstrom SA, Brown BA, Tarvin E, et al. Role of pharmacist counseling in preventing adverse drug events



- after hospitalization. *Arch Intern Med.* 2006;166(5):565-71, <http://dx.doi.org/10.1001/archinte.166.5.565>.
26. Leguelinel-Blache G, Dubois F, Bouvet S, Roux-Marson C, Arnaud F, Castelli C, et al. Improving Patient's Primary Medication Adherence: The Value of Pharmaceutical Counseling. *Medicine (Baltimore)*. 2015;94(41):e1805, <http://dx.doi.org/10.1097/MD.0000000000001805>.
27. Tedesco GW, McConaha JL, Skomo ML, Higginbotham SK. A Pharmacist's Impact on 30-Day Readmission Rates When Compared to the Current Standard of Care Within a Patient-Centered Medical Home: A Pilot Study. *J Pharm Pract.* 2016;29(4):368-73, <http://dx.doi.org/10.1177/0897190014568671>.
28. Phatak A, Prusi R, Ward B, Hansen LO, Williams MV, Vetter E, et al. Impact of pharmacist involvement in the transitional care of high-risk patients through medication reconciliation, medication education, and postdischarge call-backs (IPITCH Study). *J Hosp Med.* 2016;11(1):39-44, <http://dx.doi.org/10.1002/jhm.2493>.
29. Marcum ZA, Gellad WF. Medication adherence to multidrug regimens. *Clin Geriatr Med.* 2012;28(2):287-300, <http://dx.doi.org/10.1016/j.cger.2012.01.008>.